ArticlePloS one2013
Early gene expression analysis in 9L orthotopic tumor-bearing rats identifies immune modulation in molecular response to synchrotron microbeam radiation therapy.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Roadmap for the implementation of particle minibeam therapy.Medical physics · 2026Review
- Spatially fractionated radiotherapy and immunotherapy: a synergistic strategy for systemic anti-tumor immunity.Journal of translational medicine · 2026Review
- Mini-GRID enhances survival and reduces toxicity in an orthotopic murine model of oral squamous cell carcinoma: A proof-of-concept study.Clinical and translational radiation oncology · 2026Article
- Combining advanced radiotherapy techniques and immunotherapy: immunomodulatory mechanisms and clinical prospects.Frontiers in immunology · 2026Review
- Emerging strategies in radiation therapy: promises and challenges of spatial fractionation, ultra-high dose rates, and nanoparticles.Journal of physics D: Applied physics · 2025Review
- Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade.Science translational medicine · 2024Article
- Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio.Clinical and translational radiation oncology · 2024Review
- MRT-boost as the last fraction may be the most efficient irradiation schedule for increased survival times in a rat glioma model.Journal of synchrotron radiation · 2023Article
- Good Timing Matters: The Spatially Fractionated High Dose Rate Boost Should Come First.Cancers · 2022Article
- Preclinical dosimetry in proton minibeam radiation therapy: Robustness analysis and guidelines.Medical physics · 2022Article
- Radiobiological and Treatment-Related Aspects of Spatially Fractionated Radiotherapy.International journal of molecular sciences · 2022Review
- An investigation of kV mini-GRID spatially fractionated radiation therapy: dosimetry and preclinical trial.Physics in medicine and biology · 2022Article
- Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy.Pharmaceutics · 2022Review
- Article
- Microbeam Radiotherapy-A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma.International journal of molecular sciences · 2021Review
- Quantification of Differential Response of Tumour and Normal Cells to Microbeam Radiation in the Absence of FLASH Effects.Cancers · 2021Article
- Unexpected Benefits of Multiport Synchrotron Microbeam Radiation Therapy for Brain Tumors.Cancers · 2021Article
- Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast.Archives of toxicology · 2020Review
- Article
- Biological and Mechanical Synergies to Deal With Proton Therapy Pitfalls: Minibeams, FLASH, Arcs, and Gantryless Rooms.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synchrotron Microbeam Radiation Therapy (MRT) relies on the spatial fractionation of the synchrotron photon beam into parallel micro-beams applying several hundred of grays in their paths. Several works have reported the therapeutic interest of the radiotherapy modality at preclinical level, but biological mechanisms responsible for the described efficacy are not fully understood to date. The aim of this study was to identify the early transcriptomic responses of normal brain and glioma tissue in rats after MRT irradiation (400Gy). The transcriptomic analysis of similarly irradiated normal brain and tumor tissues was performed 6 hours after irradiation of 9 L orthotopically tumor-bearing rats. Pangenomic analysis revealed 1012 overexpressed and 497 repressed genes in the irradiated contralateral normal tissue and 344 induced and 210 repressed genes in tumor tissue. These genes were grouped in a total of 135 canonical pathways. More than half were common to both tissues with a predominance for immunity or inflammation (64 and 67% of genes for normal and tumor tissues, respectively). Several pathways involving HMGB1, toll-like receptors, C-type lectins and CD36 may serve as a link between biochemical changes triggered by irradiation and inflammation and immunological challenge. Most immune cell populations were involved: macrophages, dendritic cells, natural killer, T and B lymphocytes. Among them, our results highlighted the involvement of Th17 cell population, recently described in tumor. The immune response was regulated by a large network of mediators comprising growth factors, cytokines, lymphokines. In conclusion, early response to MRT is mainly based on inflammation and immunity which appear therefore as major contributors to MRT efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.